AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 21 min read$CNTB

HC Wainwright & Co. reiterates Buy rating on Connect Biopharma Hldgs, $7 price target

HC Wainwright & Co. maintained a Buy rating on Connect Biopharma Hldgs with a $7 price target, implying a 614.5% upside from the last close. The firm cited strong clinical data and upcoming regulatory milestones as key catalysts. Recent analyst price targets range from $5 to $7.

Original reporting
tradingview.com
Published Oct 2, 2026, 10:29 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 10:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HC Wainwright & Co. reiterates Buy rating on Connect Biopharma Hldgs, $7 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

$CNTBBullishMed
01

Why it matters

The new efficacy data and higher target are likely to attract buying interest, especially in a thinly traded microcap.

02

Market read

Provides fresh clinical data and analyst upgrade for CNTB, creating a short-term trading catalyst.

03

What to watch

Potential delays in FDA discussions and competition from other COPD therapies could temper upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Analyst note from HC Wainwright reiterates a Buy rating and raises price target to $7 based on new COPD trial data.

Company-level read

Ticker impact

$CNTBBullishHigh confidence
Context

HC Wainwright reiterated a Buy rating on Connect Biopharma Hldgs (CNTB) and highlighted new Phase 2 data showing 81% reduction in COPD treatment failure.

Expected impact

likely upward pressure as investors price in the efficacy data and higher target.

Evidence & confidence

Trial results are material for a biotech and the analyst upgrade adds credibility, driving demand.

Market effects

Sector

Boosts sentiment for respiratory biotech sector and may lift peers with similar pipelines.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Modest, primarily affecting niche biotech investors.

Counterpoint

What could challenge this read

Skeptics may question the durability of the data and regulatory timeline, suggesting caution.

Key entities

  • Company
    Connect Biopharma Holdings

    Biotech developing respiratory therapies, ticker CNTB.

  • Analyst
    HC Wainwright & Co.

    Equity research firm issuing the rating and target.

Read at source← All news

Related articles

SEP 30
$CNTBHighAI 9/10

Why is Connect Biopharma stock surging today?

Connect Biopharma (CNTB) stock rose 17.4% to $1.165 after positive Phase 2 trial results for its COPD treatment, rademikibart. The drug showed significant efficacy, reducing treatment failure rates and exacerbations. BTIG lowered its price target to $5.00 but maintained a Buy rating. Analysts generally remain positive, with a consensus price target of $6.14. The company plans to discuss Phase 3 development with the FDA. The broader market also gained due to softer inflation data.

investing.com2 min
SEP 30
$CNTBHighAI 8/10

BTIG cuts Connect Biopharma stock price target on trial timeline

BTIG reduced its price target for Connect Biopharma (CNTB) to $5.00 from $10.00, maintaining a Buy rating. The stock is down 65% YTD. The company's Seabreeze STAT COPD trial met its primary endpoint, showing an 81% reduction in treatment failure rate. BTIG lowered success probabilities and pushed launch timelines to 2030. Other analysts have mixed reactions, with some reiterating Buy ratings and others adjusting targets.

investing.com2 min
SEP 30
$CNTBHighAI 9/10

Connect Biopharma stock jumps on positive COPD trial data

Connect Biopharma (NASDAQ:CNTB) shares rose 25% after reporting positive Phase 2 trial results for rademikibart, a drug candidate for COPD. The study showed significant reductions in treatment failure, exacerbations, and hospitalizations compared to placebo. The company plans to discuss a Phase 3 program with the FDA and may receive up to $99 million in milestone payments from Simcere Pharmaceutical.

investing.com2 min
SEP 30
$CNTBHighAI 9/10

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in…

Connect Biopharma Holdings Ltd (CNTB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation – Rademikibart significantly reduced the rate of treatment failure c

SEC EDGAR 8-K2 min
SEP 30
$CNTBHighAI 9/10

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

Connect Biopharma (CNTB) reported positive Phase 2 data for rademikibart, showing an 81% reduction in treatment failure and 85% fewer new COPD exacerbations vs. placebo. The drug also eliminated hospitalizations/ED visits. The company plans to discuss the results with the FDA and host a conference call today.

globenewswire.com2 min